A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 - present)
{{output}}
Introduction: The SARS-CoV-2 main protease (Mpro, also known as 3CLpro or nsp5) is essential for viral replication. As there are no close human homologs, it represents an attractive and specific target for antiviral therapy again... ...
